Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Claudia Pauligk, Johannes Meiler, Ralf Dieter Hofheinz, Hans-Georg Kopp, Frank Mayer, Harald Schmalenberg, Kim Luley, Georg Martin Haag, Wolff H. Schmiegel, Nils Homann, Stephan Probst, Michael Koenigsmann, Nicole Prasnikar, Jorg Trojan, Matthias Egger, Rolf Mahlberg, Michael Heike, Andrea Tannapfel, Elke Jäger, Salah-Eddin Al-Batran
Institutions: Krankenhaus Nordwest, Essen University Hospital, University of Duisburg-Essen, University Medical Centre Mannheim, University of Tübingen, Jena University Hospital, University of Lübeck, National Center for Tumor Diseases, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Klinikum Bielefeld, Klinikum Ludwigsburg, Goethe University Frankfurt, Ortenau Klinikum, Klinikum Mutterhaus der Borromäerinnen, Klinikum Dortmund, BG University Hospital Bergmannsheil Bochum
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2745823917